Literature DB >> 32152143

Severe dysfunctional tear syndrome patients and resolution of central corneal staining: retrospective cohort study.

Zhen Ling Teo1,2, Clarisse Chu1, Louis Tong3,2,4,5.   

Abstract

PURPOSE: Severe dry eye is widely prevalent yet difficult to treat. This study aims to evaluate for improvement in epithelial status and the risk factors for lack of improvement in a cohort of patients in Singapore with severe dry eye.
METHODS: We retrospectively identified 1712 patients with severe dry eye (≥grade 3 Delphi) in at least one eye, referred to a tertiary centre dry eye clinic from 2006 to 2017. We included patients with central corneal staining grade of ≥2 at referral and minimum follow-up duration of 6 months (n=407). An epithelial staining grade of <2 at the last visit was considered a significantly improved outcome.
RESULTS: The mean follow-up duration was 4.0±2.4 years, with 88.0% (358/407) of patients achieving significant improvement. Various treatment modalities including topical corticosteroids (32.4%), cyclosporine (52.8%) and punctal plugs (24.1%) were used. Risk factors for non-improvement of staining grade include autoimmune disease (OR 3.2, 95% CI: 1.7 to 6.1), rheumatoid arthritis (RA) (OR 3.4 (1.8 to 6.6)), graft-versus-host disease (GVHD) (OR 3.4 (1.0 to 11.7)), reduced baseline Schirmer's test (OR 2.1 (1.2 to 3.9)) and reduced tear break up time (OR 2.0 (1.0 to 3.8)). On multivariate analyses, RA and GVHD were still significant risk factors. Gender, age and meibum viscosity were not significantly associated with epithelial staining grade improvement.
CONCLUSIONS: Overall, a high rate of corneal epithelial improvement was achieved. Nevertheless, there is an unmet need for more effective measures to reduce epitheliopathy in severe dry eye, especially in patients with systemic immune-mediated disease. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cornea; ocular surface; tears; treatment other

Mesh:

Year:  2020        PMID: 32152143     DOI: 10.1136/bjophthalmol-2019-315573

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  2 in total

1.  Assessment and Management of Dry Eye Disease and Meibomian Gland Dysfunction: Providing a Singapore Framework.

Authors:  Louis Tong; Li Lim; Donald Tan; Wee Jin Heng; Jimmy Lim; Cordelia Chan; Anshu Arundhati; Anna Tan
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2021-11-11

2.  A Practical Approach to Severity Classification and Treatment of Dry Eye Disease: A Proposal from the Mexican Dry Eye Disease Expert Panel.

Authors:  Alejandro Rodriguez-Garcia; Alejandro Babayan-Sosa; Arturo Ramirez-Miranda; Concepcion Santa Cruz-Valdes; Everardo Hernandez-Quintela; Julio C Hernandez-Camarena; Nallely Ramos-Betancourt; Regina Velasco-Ramos; Raul E Ruiz-Lozano
Journal:  Clin Ophthalmol       Date:  2022-04-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.